A multicenter, randomized, placebo-controlled, double-blind trial to evaluate the effects of vasopressin V2 receptor antagonist on clinical improvement in patients with severe chronic heart failure

Trial Profile

A multicenter, randomized, placebo-controlled, double-blind trial to evaluate the effects of vasopressin V2 receptor antagonist on clinical improvement in patients with severe chronic heart failure

Completed
Phase of Trial: Phase II

Latest Information Update: 16 Jun 2008

At a glance

  • Drugs Satavaptan (Primary)
  • Indications Chronic heart failure; Heart failure
  • Focus Therapeutic Use
  • Acronyms AQUAVIT
  • Sponsors Sanofi-Synthelabo
  • Most Recent Events

    • 16 Jun 2008 Actual patient number 338 added as reported by ClinicalTrials.gov
    • 16 Jun 2008 Actual end date changed from Sep 2002 to Feb 2003 as reported by ClinicalTrials.gov.
    • 14 Sep 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top